Prediction of the change in bone mineral density induced by gonadotropin-releasing hormone agonist treatment for endometriosis

Fertility and Sterility

Volumn 81, Issue 1, 2004, Pages 149-153

  Matsuo, Hiroya ^a  

^a KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bone mineral density; Deoxypyridinoline; Endometriosis; GnRH agonist

Indexed keywords

DEOXYPYRIDINOLINE; GONADORELIN AGONIST; LEUPRORELIN;

ADULT; ARTICLE; BLOOD SAMPLING; BONE DENSITY; BONE METABOLISM; BONE MINERAL; BONE TURNOVER; CONTROLLED STUDY; CORRELATION ANALYSIS; DUAL ENERGY X RAY ABSORPTIOMETRY; ENDOMETRIOSIS; FEMALE; GENERAL HOSPITAL; GYNECOLOGY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; OBSTETRICS; OSTEOPOROSIS; PREDICTION; PRIORITY JOURNAL; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; URINALYSIS;

EID: 0346095178     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2003.05.022     Document Type: Article

References (17)

1. Wheeler J.M., Knittle J.D., Miller J.D. Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis I. Efficacy results . Am J Obstet Gynecol. 167:1992;1367-1371.
2. Dlugi A.M., Miller J.D., Knittle J. Lupron depot in the treatment of endometriosis a randomized, placebo controlled double-blind study . Fertil Steril. 54:1990;419-427.
3. Franke H.R., van de Weijer P.H.M., Pennings T.M.M., van der Mooren M.J. Gonadotropin-releasing hormone agonist plus "add-back" hormone replacement therapy for treatment of endometriosis a prospective, randomized, placebo-controlled, double blind trial . Fertil Steril. 74:2000;534-539.
4. Irahara M., Uemura H., Yasui T., Kinoshita H., Yamada M., Tezuka M., et al. Efficacy of every-other-day administration of conjugated equine estrogen and medroxyprogesterone acetate on gonadotropin-releasing hormone agonists treatment in women with endometriosis. Gynecol Obstet Invest. 52:2001;217-222.
5. Moghissi K.S., Schlaff W.D., Olive D.L., Skinner M.A., Yin H. Goserelin acetate (Zoladex) with or without hormone replacement therapy for the treatment of endometriosis. Fertil Steril. 69:1998;1056-1062.
6. Pierce S.J., Gazvani M.R., Farquharson R.G. Long-term use of gonadotropin-releasing hormone analogs and hormone replacement therapy in the management of endometriosis a randomized trial with a 6-year follow-up . Fertil Steril. 74:2000;964-968.
7. Hui S.L., Gao S., Zhou X., Johnston C.C., Lu Y., Gluer C.C., et al. Universal standardization of bone density measurements a method with optimal properties for calibration among several instruments . J Bone Miner Res. 12:1997;1463-1470.
8. Katase K., Kato T., Hirai Y., Hasumi K., Cjen J.T. Effect of ipriflavone on bone loss following a bilateral ovariectomy and menopause a randomized placebo-controlled study . Calcif Tissue Int. 69:2001;73-77.
9. Barrett-Connor E., Young R., Notelovitz M., Sullivan J., Wiita B., Yang H.M., et al. A two-year, double blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women. Effects on bone mineral density, symptoms and lipid profiles. J Reprod Med. 44:1999;1012-1020.
10. Jilka R.L., Hangoc G., Girasole G., Passeri G., Williams D.C., Abrams J.S., et al. Increased osteoclast development after estrogen loss mediation by interleukin-6 . Science. 257:1992;88-91.
11. Shevde N.K., Bendixen A.C., Dienger K.M., Pike J.W. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independant mechanism involving c-Jun repression. Proc Natl Acad Sci USA. 97:2000;7829-7834.
12. Borderie D., Cherruau B., Dougados M., Ekindjian O.G., Roux C. Biochemical markers as predictors of bone mineral density changes after GnRH agonist treatment. Calcif Tissue Int. 62:1998;21-25.
13. Rosen C.J., Chesnut C.H. III, Mallinak N.J.S. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab. 82:1997;1904-1910.
14. Gonnelli S., Cepollaro C., Pondrelli C., Martini S., Monaco R., Gennari C. The usefulness of bone turnover in predicting the response to transdermal estrogen therapy in postmenopausal osteoporosis. J Bone Miner Res. 12:1997;624-631.
15. Surrey E.S., Hornstein M.D. Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis long-term follow-up . Obstet Gynecol. 99:2002;709-719.
16. Mukherjee T., Barad D., Turk R., Freeman R. A randomized, placebo-controlled study on the effect of cyclic intermittent etidronate therapy on the bone mineral density changes associated with six months of gonadotropin-releasing hormone agonist treatment. Am J Obstet Gynecol. 175:1996;105-109.
17. Palomba S., Orio F., Morelli M., Russo T., Pellicano M., Nappi C., et al. Raloxifene administration in women treated with gonadotroipin-releasing hormone agonist for uterine leiomyomas effects on bone metabolism . J Clin Endocrinol. 87:2002;4476-4481.